The U.S. Supreme Court this morning unanimously rejected an attempt to roll back access to the abortion pill, a decision applauded by the National Asian Pacific American Women’s Forum (NAPAWF).
The justices agreed that the plaintiff in the case, Alliance for Hippocratic Medicine, lacked legal standing because they could not prove they’ve been adversely impacted by the drug’s availability.
The ruling keeps the drug mifepristone available but does not rule out the possibility another plaintiff could issue a similar challenge.
“It’s a win that the status quo is preserved but it doesn’t signal that these are now dead arguments that others aren’t going to try and pursue,” said Rachel Rebouche, a Temple University law professor, to ABC News.
“NAPAWF is relieved that today’s SCOTUS decision will sustain access to medication abortion,” Sung Yeon Choimorrow, NAPAWF’s Executive Director, said in a statement to AsAmNews. “This decision means that, for now, access to this highly effective, safe, and life-saving medication will remain unchanged.”
This was the first time the Supreme Court has been asked to overrule a decision by the Food and Drug Administration, which deemed mifepristone safe. USA Today reported that drug makers had warned that doing so would have thrown the drug industry into chaos.
“We still have a long way to go before achieving true reproductive justice in this country. Several states have already banned or restricted medication abortion and we expect that, regardless of the outcome of this case, those efforts will continue,” Choimorrow said.
AsAmNews is published by the non-profit, Asian American Media Inc.
We are supported through donations and such charitable organizations as the Robert Wood Johnson Foundation. A big thank you to all our readers who supported our year-end giving campaign. You helped us not only reach our goal, you busted through it. Donations to Asian American Media Inc and AsAmNews are tax-deductible. It’s never too late to give.
Please also follow us on Instagram, TikTok, Facebook, YouTube and X.